drugset
drugset / Trial / NCT04119947

Single Ascending Oral Doses of SY-009 in Healthy Subjects

NCT04119947 ↗

Phase 1 Completed 24 enrolled Suzhou Yabao Pharmaceutical R&D Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase Ⅰ，single-center, randomized, double-blinded, placebo-controlled, single ascending dose trial of SY-009 in healthy subjects.

Timeline

Start
2019-03-01
Primary completion
2019-05-30
Completion
2019-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SY-009 Unknown 0.5 mg Oral
Subject SY-009 Unknown 2 mg Oral
Subject SY-009 Unknown 5 mg Oral
Subject SY-009 Unknown 10 mg Oral
Subject SY-009 Unknown 20 mg Oral
Subject SY-009 Unknown 40 mg Oral

Indications

diabetes mellitus